CD34 Cancer Research Results

CD34, CD34 transmembrane phosphoglycoprotein protein: Click to Expand ⟱

Source:

Type:

CD34 is a transmembrane phosphoglycoprotein protein that is expressed on the surface of certain cells, including hematopoietic stem cells, endothelial progenitor cells, and some cancer cells. In the context of cancer, CD34 has been studied as a potential biomarker and therapeutic target.
CD34 has been shown to be expressed on cancer stem cells in various types of cancer, including leukemia, breast cancer, and lung cancer.

BC, Breast Cancer: Click to Expand ⟱

Breast Cancer

Scientific Papers found: Click to Expand⟱

4936-

PEITC,

PEITC treatment suppresses myeloid derived tumor suppressor cells to inhibit breast tumor growth

in-vivo,

BC,

MDA-MB-231

Breast tumors are heterogeneous with a complex etiology. The immune system plays a crucial role in the development of tumors and can facilitate tumor growth pleiotropically. Myeloid derived suppressor cells (MDSCs) generate reactive oxygen species (ROS) and cytokines to suppress T cells, dendritic cells and natural killer (NK) cells. Hence, the inhibition of MDSCs could be an important strategy for anticancer therapeutics. Phenethyl isothiocyanate (PEITC), a bioactive compound present in cruciferous vegetables, is known to have anticancer properties. However, the effects of PEITC administration on the immune system have not been previously reported. In the current study, we evaluated the effects of administering PEITC to immunocompromised NOD-SCID IL2Rγ−/− (SCID/NSG) host mice bearing MDA-MB-231 xenografts on MDSCs in the peripheral blood. Our results reveal that oral administration of 12 μmol PEITC attenuated tumor growth by 76%. This was marked tumor-inhibitory phenotype was associated with a significant reduction in the levels of MDSCs bearing the surface markers CD33, <span class="wphighlight">CD34</span> and CD11b in PEITC treated mice, indicating that overall tumor growth suppression by PEITC correlates with inhibition of MDSCs. To the best of our knowledge, this is the first study showing effects of PEITC on MDSCs.

TumCG↓, CD34↓, CD11b↓, CSCs↓, ALC∅, CD4+↓, NF-kB↓, STAT3↓, Hif1a↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Clinical Biomarkers ⓘ

ALC∅, 1,
Total Targets: 9

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: CD34, CD34 transmembrane phosphoglycoprotein protein

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:4  Cells:%  prod#:%  Target#:629  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

CD34 Cancer Research Results

Pathway results for Effect on Cancer / Diseased Cells:

Proliferation, Differentiation & Cell State ⓘ

Migration ⓘ

Angiogenesis & Vasculature ⓘ

Immune & Inflammatory Signaling ⓘ

Clinical Biomarkers ⓘ

Pathway results for Effect on Normal Cells:

Home Page